Table 2.

Weight loss effect of liraglutide in the SCALE series.

Trial name	Study population	Study design	Duration	Weight loss			Statistical significance
				Placebo	1.8 mg	3.0 mg
SCALE – diabetes	n = 846 Age 18 years or older BMI 27.0 or higher T2DM Up to 3 oral hypoglycaemic agents	Any sulfonylurea reduced by 50%, other oral hypoglycaemics continue Lifestyle intervention	56 weeks	−2.0%	−4.7%	−6.0%	p = <0.001 for 1.8 mg and 3.0 mg doses versus placebo
		Study arms: 1) Liraglutide 1.8 mg 2) Liraglutide 3.0 mg 3) Liraglutide placebo
SCALE – pre-diabetes	n = 3731 Age 18 years or older BMI 30.0 or higher, or 27.0 or higher with hypertension or dyslipidaemia No diabetes	Lifestyle intervention	56 weeks	−2.6%	N/A	−8.0%	p = <0.001 versus placebo
		Study arms (1) liraglutide 3.0 mg; (2) liraglutide placebo.
SCALE - Maintenance	Age 18 years or older BMI 30.0 or higher, or 27.0 or higher with hypertension or dyslipidaemia Previous unsuccessful attempts at dietary weight loss No diabetes	12-week low calorie run-in Patients with weight loss of 5% or greater continued into study	56 weeks	−0.2% (in addition to run-in weight loss)	N/A	−6.2% (in addition to run-in weight loss	p = <0.0001 versus placebo
		Study arms: (1) liraglutide 3.0 mg; (2) liraglutide placebo.
SCALE – Sleep Apnoea	Age 18–64 years BMI 30.0 or higher Moderate or severe obstructive sleep apnoea Unable or unwilling to use CPAP No diabetes	Lifestyle intervention	36 weeks	−1.6%	N/A	−5.7%	p < 0.0001 versus placebo
		Study arms: (1) liraglutide 3.0 mg; (2) liraglutide placebo.

OHG, Oral hypoglycaemic; T2DM, type 2 diabetes mellitus; BMI, body mass index; CPAP, continuous positive airway pressure; N/A, not available.